Analyst Price Targets — ATR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 12:03 pm | — | Raymond James | $160.00 | $130.38 | TheFly | AptarGroup price target raised to $160 from $150 at Raymond James |
| February 9, 2026 12:16 pm | — | Robert W. Baird | $156.00 | $134.31 | TheFly | AptarGroup price target raised to $156 from $145 at Baird |
| January 9, 2026 12:58 pm | Paul Knight | KeyBanc | $220.00 | $124.56 | StreetInsider | KeyBanc Reiterates Overweight Rating on AptarGroup (ATR) |
| November 3, 2025 12:18 pm | Ghansham Panjabi | Robert W. Baird | $145.00 | $116.01 | TheFly | AptarGroup price target lowered to $145 from $160 at Baird |
| November 3, 2025 11:05 am | — | Wells Fargo | $133.00 | $116.01 | TheFly | AptarGroup price target lowered to $133 from $152 at Wells Fargo |
| October 28, 2024 6:54 am | Ghansham Panjabi | Robert W. Baird | $185.00 | $169.63 | StreetInsider | AptarGroup (ATR) PT Raised to $185 at Baird |
| October 14, 2024 3:26 am | Daniel Rizzo | Jefferies | $215.00 | $161.55 | StreetInsider | Jefferies Upgrades AptarGroup (ATR) to Buy |
| September 1, 2023 1:48 pm | Thomas Blakey | Loop Capital Markets | $45.00 | $132.55 | Benzinga | Nutanix Set To Outperform With Strong FCF And Hybrid Cloud Focus, Despite Macro Challenges: Analyst |
| August 2, 2022 8:22 am | — | Morgan Stanley | $120.00 | $108.20 | Benzinga | Morgan Stanley Maintains Equal-Weight on AptarGroup, Lowers Price Target to $120 |
| August 1, 2022 9:57 am | — | Robert W. Baird | $110.00 | $108.06 | Benzinga | Baird Maintains Neutral on AptarGroup, Lowers Price Target to $110 |
Latest News for ATR
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease -- SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics…
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.